POLA PENGGUNAAN OBAT ANTIRETROVIRAL (ARV) PADA RESEP PASIEN RAWAT JALAN DARI KLINIK HIV/AIDS SALAH SATU RUMAH SAKIT SWASTA DI KOTA BANDUNG
DOI:
https://doi.org/10.33759/jrki.v1i1.10Keywords:
Antiretroviral, HIV/AIDS, Pattern of Drug UseAbstract
ABSTRACT
The Human Immunodeficiency Virus (HIV) continues to be a major global public health issue, which targets the human immune system. The using of ARVs in the treatment of HIV / AIDS increased life expectancy for PLHIV (People With HIV / AIDS). This study aims to determine the description of the using of ARV drugs in outpatients of the HIV / AIDS Clinic and assessed their suitability with established treatment standards. This research was carried out in a descriptive non-experimental manner, with data collection carried out retrospectively, used patient prescription data from April to December 2017. The results of quantitative studies showed 87% were male patients, and the largest age group was 20-29 years (39%) . Class of antiretroviral drugs used were Nucleoside / Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Protease Inhibitors (PI), with a combination of antiretroviral drugs most was the combination of first-line tenofovir + lamivudine + efavirenz (69%) while the second-line drug zidovudine + lamivudine + lopinavir / ritonavir was 1%. The most commonly used comorbid drug was cotrimoxazole. For qualitative data, the accuracy of combination and dose of ARV drugs was 100% in accordance with Permenkes No. 87/ 2014, with 79% of patients adhered to antiretroviral treatment every month. The potential for most ARV drug interactions with other drugs for the moderate category was zidovudin + cotrimoxazole (11%) which occured pharmacokinetically by decreasing renal clearance of zidovudine and glucuronide metabolites. In conclusion, the pattern of used of ARV drugs had met the standard of Permenkes No.87/2014, with the most used were the first line combination of tenofovir + lamivudine + efavirenz.
Downloads
References
Ditjen P2P Kemenkes RI (2016) : Laporan Perkembangan HIV-AIDS dan Penyakit Infeksi Menular Seksual (PIMS) Triwulan III Tahun 2016, Kementerian Kesehatan RI, Jakarta.
Ditjen P2P Kemenkes RI (2017) : Laporan Perkembangan HIV-AIDS dan Penyakit Infeksi Menular Seksual (PIMS) Triwulan I Tahun 2017, Kementerian Kesehatan RI, Jakarta.
Jamil, K.F (2014) : Profil Kadar CD4 terhadap Infeksi Oportunistik pada Penderita Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV/AIDS) di RSUD DR.Zainoel Abidin Banda Aceh, Jurnal Kedokteran Syiah Kuala, 14(2), 79.
Katzung, B.G. dan Trevor, A.J. (2015) : Basic and Clinical Pharmacology, Thirteenth Edition, McGraw-Hill Education, New York, 1244-1257.
Kusumayanti, R.R., Yunihastuti, E., Purnamasari, D., Witjaksono, F., dan Dewiasty E. (2015) : Faktor-Faktor yang Berperan terhadap Terjadinya Lipodistrofi pada Pasien HIV yang Mendapatkan Terapi Antiretroviral Lini Pertama, Jurnal Penyakit Dalam Indonesia, 2 , 223.
Menteri Kesehatan RI (2014) : peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2014 tentang Pedoman Pengobatan Antiretroviral, Kementerian Kesehatan RI, Jakarta, 7-65.
Pusdatin Kemenkes RI (2016) : Situasi Penyakit HIV AIDS di Indonesia, Kementerian Kesehatan RI, Jakarta, 1-
Siregar, C.J.P. dan Kumolosasi. E. (2006) : Farmasi Klinik : Teori dan Terapan, Cetakan I, Penerbit Buku Kedokteran EGC, Jakarta, 306-307.
Surilena dan Valeri J.(2015) : Knowledge of HIV-AIDS a dominant factor of antiretroviral theraupetic adherence in women with HIV-AIDS, Universa Medicina, 34(2), 129.
Tatro, D. (2014) : Drug Interaction Facts, Facts and Comparison Publishing Group, California, xiii-xvii, 249, 299, 1408, 1125, 2170, 2180.
WHO (2016) : Consolidated Guidelines on The Use of Antiretroviral Drugs for Treating and Preventing HIV infection, 2nd Edition, WHO Press, Switzerland, 388-395.
WHO (2017) : Elimination of Mother- to-Child Transmission of HIV (EMTCT), http://www.who.int /mediacentre / factsheets /fs360/en/, diakses tanggal 13 Maret 2018.
WHO (2017) : HIV/AIDS Key Facts, http://www.who.int/ mediacentre/factsheets/ fs360 /en/, diakses tanggal 11 Oktober 2017.
WHO (2017) : HIV Drug Resistance, http://www.who.int/hiv/topics /drugresistance/en/, diakses tanggal 11Oktober 2017.
Widiyanti, M., Sandy, S., Fitriana, E. (2015) : Dampak Perpaduan Obat ARV pada pasien HIV/AIDS ditinjau dari kenaikan Jumlah Limfosit CD4+ di RSUD Dok II Kota Jayapura, PLASMA, 1(2), 53-58.
